1,861,020 Shares in Solventum Corporation $SOLV Bought by Norges Bank

Norges Bank bought a new position in Solventum Corporation (NYSE:SOLV) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,861,020 shares of the company’s stock, valued at approximately $147,467,000. Norges Bank owned 1.07% of Solventum at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SOLV. United Services Automobile Association bought a new position in Solventum in the first quarter worth $239,000. Woodline Partners LP lifted its position in Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after purchasing an additional 3,377 shares during the period. Intech Investment Management LLC lifted its position in Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after purchasing an additional 10,425 shares during the period. First Trust Advisors LP lifted its position in Solventum by 5.8% in the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock worth $19,546,000 after purchasing an additional 14,151 shares during the period. Finally, Marshall Wace LLP bought a new position in Solventum in the second quarter worth $766,000.

Solventum Stock Performance

Solventum stock opened at $78.39 on Thursday. The stock has a 50-day simple moving average of $70.21 and a 200 day simple moving average of $75.12. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20. The stock has a market capitalization of $13.58 billion, a price-to-earnings ratio of 9.61, a P/E/G ratio of 1.18 and a beta of 0.69.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the previous year, the business posted $1.34 earnings per share. The firm’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Insider Activity

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.24% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently commented on SOLV. Wedbush began coverage on Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target on the stock. Stifel Nicolaus cut their price objective on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Thursday, May 14th. Finally, Wells Fargo & Company cut their price objective on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Solventum presently has an average rating of “Moderate Buy” and a consensus price target of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.